Clinomic Shapes the Future of AI-Driven Medicine as Key Partner in EU Project SCAILED

Clinomic is proud to participate as a key beneficiary in a landmark European initiative: the EU-funded project SCAILED (Scale-up Biotech AI Innovation by Leveraging Responsible Data Use under the European Health Data Space). Clinomic brings deep technical, clinical, and regulatory expertise to the consortium.

Officially launched in October 2026, the 36-month SCAILED project aims to accelerate the development, deployment, and scaling of Artificial Intelligence (AI) and digital health solutions across Europe. The initiative harnesses high-quality health data within the secure and interoperable framework of the European Health Data Space (EHDS) under Regulation (EU) 2025/327.

With a total budget of €18 million, including €14.4 million (80%) in funding from the EU4Health programme, the SCAILED consortium brings together 50 partner organizations across 17 EU Member States. The consortium addresses critical technical, operational, and regulatory barriers to strengthen European competitiveness in digital health and biotech innovation.

AI-Driven Medicine: Clinomic’s Role in SCAILED

Clinomic brings deep technical, clinical, and regulatory expertise to the consortium. Clinomic’s key contributions focus on three core pillars:

1. Leading Critical Care AI Innovation 

Clinomic is leading a use case focused on AI-driven prevention, diagnosis, and management of delirium in Intensive Care Unit (ICU) patients. Leveraging our expertise in critical care technology:

• Federated Data Infrastructure: Clinomic provides a federated learning architecture for data standardization using international standards (HL7 FHIR IPS and SNOMED CT), enabling secure, cross-border health data reuse across European ICU centers.
• Decision Support at the Bedside: The goal is to deploy a prototype Clinical Decision Support System (CDSS) capable of delivering rapid diagnosis and personalized treatment plans, directly interfacing with hospital Patient Data Management Systems (PDMS) to reduce patient morbidity, length of stay, and ICU operational costs.

2. Pioneering Regulatory Clarity and Ethics

Developing and deploying clinical AI requires navigating a complex regulatory landscape, including the EU AI Act, Medical Device Regulation (MDR), GDPR, and the evolving EHDS framework. Clinomic contributes by:

• Sharing industry and operational insights to help resolve legal hurdles.
• Establishing transparent guidelines to streamline market access and safe clinical adoption of AI technologies.

3. Integration with AI Factories & Infrastructure Scale-Up

Clinomic works alongside European AI Factories, Health Data Access Bodies (HDABs), and supercomputing centers to ensure that technical pipelines for federated learning, data anonymization, and secure data processing can be translated into scalable, production-level medical services beyond the pilot phase.

A Powerful Multi-Stakeholder Consortium

Coordinated by the Luxembourg National Data Service (LNDS), the SCAILED consortium unites 50 partners, including health data authorities, university hospitals, research infrastructures, supercomputing centers, biotech innovators, and patient advocacy groups.

By driving real-world ICU integration and shaping regulatory pathways, Clinomic reinforces its commitment to delivering trustworthy, life-saving AI technologies to acute and intensive care environments across Europe.

Interested in learning more about our research initiatives or our AI solutions for intensive care?

Get in touch with our team or follow our channels for ongoing updates on the SCAILED project!